Accuray Inc., maker of the CyberKnife radiosurgery system, has received FDA 510(k) clearance for Lung Optimized Treatment, a new component of CyberKnife that allows for accurate lung tracking without using fiducial markers.
Lung Optimized Treatment offers the accuracy and steep dose fall off required to safely treat lung tumors, even those close to such critical structures. Simulation and comparison workflows, combined with unique tracking modes, allow the clinician to select from multiple, non-invasive options, providing lung SBRT patients the optimal non-invasive treatment option, regardless of tumor location.
Because fiducial implantation is no longer required, CyberKnife radiosurgery with Lung Optimized Treatment offers a completely non-invasive option, which is particularly important for medically or surgically inoperable patients. This means patients who are not candidates for fiducial placement or physicians who choose not to implant fiducials due to the high risk of pneumothorax, now have a non-invasive alternative using the CyberKnife System’s unique tracking and correction capabilities.
Press release: Accuray Receives FDA Clearance for the CyberKnife® System’s Lung Optimized Treatment…
Product page: CyberKnife VSI System…